Please login to the form below

Not currently logged in
Email:
Password:

liver disease

This page shows the latest liver disease news and features for those working in and with pharma, biotech and healthcare.

Roche enters NASH race with deal to buy Jecure

Roche enters NASH race with deal to buy Jecure

Roche is playing catch-up with a host of other companies trying to bring forward drugs for NASH and other form of fatty liver disease, with dozens of candidates already in ... Among these, Intercept’s Ocaliva (obeticholic acid) is already approved to

Latest news

  • Gilead NASH drug clears mid-stage trial, but rivals are looming Gilead NASH drug clears mid-stage trial, but rivals are looming

    Positive results to challenge Intercept in emerging disease area. Gilead has new data backing up its liver disease candidate GS-9674 in non-alcoholic steatohepatitis (NASH), tipped as one of the ... Meanwhile, Gilead also reported phase 2 results with

  • AbbVie sues NHS England over hep C procurement AbbVie sues NHS England over hep C procurement

    There have been some signs of progress in HCV, with Public Health England reporting in the summer that last year deaths from hepatitis C-related end-stage liver disease fell by

  • Novartis and Pfizer to collaborate on NASH combinations Novartis and Pfizer to collaborate on NASH combinations

    Non-Alcoholic Steatohepatitis ( NASH) has been ‘the next big thing’ for a few years now, with many big pharma licensing deals for new treatments for the fatty liver disease, and racing ... Characterised by a build-up of fat that can lead to fibrosis,

  • NICE says no to AZ and Vifor’s rival hyperkalaemia drugs NICE says no to AZ and Vifor’s rival hyperkalaemia drugs

    Most common in patients with poor kidney function, heart failure or liver disease, hyperkalemia can be fatal, and patients have had few options for treatment until now. ... The companies argue that this exposes patients to cardiovascular disease risk,

  • Alexion targets RNAi with $637m Dicerna deal Alexion targets RNAi with $637m Dicerna deal

    The drug technology platform produces compounds that inhibit complement activation, and it can be applied across multiple therapeutic areas, including cardiovascular diseases, viral infectious disease and liver diseases. ... The new deal adds to others

More from news
Approximately 9 fully matching, plus 89 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    Collaboration for. development. $760m. Enterome/. Takeda. EB8018 for Crohn’s disease and other gastrointestinal. ... Dicerna/. Lilly. GalXC RNAi technology platform for targets in Cardiometabolic disease, neurodegeneration and pain.

  • Gene therapy Gene therapy

    This is reflected in the large number of companies focusing on liver disease, as liposomal delivery vehicles tend to accumulate in the liver, or where the mode of delivery offers targeting ... targets. The overt focus on liver disease has led to one new

  • Deal Watch April 2016 Deal Watch April 2016

    265 . Intellia (US). Regeneron (US). Co-development &co-commercialisation. Discovery stage CRISPR/Cas platform for treatments of liver disease. ... 72 . Synta (US). Madrigal (US). Company acquisition. Phase I compound for treatment of liver disease.

  • AbbVie: New firm, new thinking AbbVie: New firm, new thinking

    And obviously the NHS saves on downstream costs associated with HCV, such as liver disease and the prospect of liver transplants. ... Liver disease is still one of the biggest killers in the UK and it's the only one of the top five that's actually not

  • Case study: Liver disease burden Case study: Liver disease burden

    out to and engage with stakeholders who can lead the way in addressing liver disease. ... As a result the All-Party Parliamentary Hepatology Group (APPHG) conducted an expert inquiry into liver disease.

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

  • Dr Kunwar Shailubhai appointed CEO of Tiziana Life Sciences Dr Kunwar Shailubhai appointed CEO of Tiziana Life Sciences

    manage this disease.”. ... Shailubhai takes the helm as Tiziana focuses on developing an orally administered, anti-CD3 mAb (foalumab) drug candidate to manage non-alcoholic steatohepatitis (NASH) - a liver disease that has no treatment

  • GLI names VP of scientific and regulatory affairs GLI names VP of scientific and regulatory affairs

    Food and Drug Administration and at several leading pharmaceutical companies, he brings to GLI extensive industry experience that will help us identify opportunities to transform the field of liver disease.”. ... Liver disease affects over 30 million

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Living with NASH: An Unexpected Diagnosis

    Published in eyeforpharma November 2017 by Mariel Metcalfe. With no current licensed treatments and more than 20 compounds in phase II and III, the liver disease non-alcoholic steatohepatitis (NASH) represents ... And, because it’s relatively unknown,

  • Infographic: HCV - The Roadblocks to Effective Treatment

    Hepatitis C is a chronic infection of the liver caused by the caontagious hepatitis C virus (HCV). ... blood-borne, the virus attacks cells in the liver where is multiplies causing inflammation,  cirrhosis and ultimately liver failure.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics